Surgical Stabilizer Assisted RVC With rtPA for CRVO

Status Withdrawn

Clinical Trial Summary

This phase Ib study investigates the safety and efficacy of performing a retinal vein cannulation with recombinant tissue Plasminogen Activator infusion into a retinal vein with the help of an updated dedicated surgical stabiliser for the treatment of central retinal vein occlusion.

Clinical Trial Description

Investigator-initiated, unmasked, single-arm, mono-center, prospective, interventional case series phase Ib trial. In line with the previous phase I trial, this trial will be biphasic; first 3 patients will be included, when the procedure and product prove to be safe and an added value is noted from the intra-operative OCT-angiography, another 3 will be included afterwards (≥21 days between last inclusion of the first group and first inclusion of the second group). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03417401
Study type	Interventional
Source	Universitaire Ziekenhuizen KU Leuven
Contact
Status	Withdrawn
Phase	Phase 1
Start date	October 16, 2018
Completion date	December 10, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01969708` - Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)	Phase 3
Completed	`NCT02390245` - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study	N/A
Completed	`NCT01231633` - Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)	N/A
Terminated	`NCT00969293` - Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion	Phase 1
Completed	`NCT03981549` - Treatment of Central Retinal Vein Occlusion Using Stem Cells Study	Phase 1/Phase 2
Completed	`NCT02274259` - Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen	Phase 4
Completed	`NCT01360385` - Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With Intravitreal Ranibizumab	N/A
Not yet recruiting	`NCT00383773` - Retinal Endo Vascular Surgery for Central Retinal Vein Occlusion	N/A
Completed	`NCT00952614` - A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion	N/A
Recruiting	`NCT04601701` - Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.	N/A
Completed	`NCT01976312` - Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)	Phase 3
Completed	`NCT01724554` - Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion	Phase 1/Phase 2
Completed	`NCT01471691` - Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab	Phase 1/Phase 2
Active, not recruiting	`NCT01011374` - Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion	Phase 1
Completed	`NCT03223714` - Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion	Phase 3
Recruiting	`NCT01827722` - Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion	Phase 4
Completed	`NCT00906685` - Bevacizumab for Central Retinal Vein Occlusion Study	Phase 3
Active, not recruiting	`NCT04793100` - Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections	N/A
Recruiting	`NCT02405741` - Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients	Phase 2
Recruiting	`NCT01348633` - Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye	N/A